$OGEN
ORAGENICS INC Stock $ogen

$ogen Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040060 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$7.466K	$86.05K
YoY Change		-91.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.754M	$1.330M	$1.215M
YoY Change	98.55%	9.46%	43.43%
% of Gross Profit
Research & Development	$11.04M	$769.4K	$2.825M
YoY Change	682.05%	-72.76%	-20.37%
% of Gross Profit
Depreciation & Amortization	-$2.610K	$10.00K	$12.74K
YoY Change	-119.95%	-21.51%	32.16%
% of Gross Profit
Operating Expenses	$12.80M	$2.102M	$4.040M
YoY Change	457.45%	-47.97%	-8.08%
Operating Profit		-$2.094M	-$3.954M
YoY Change		-47.02%	-10.03%
Interest Expense	$26.40K	$14.17K	$5.228K
YoY Change	-56.85%	171.04%	-51.19%
% of Operating Profit
Other Income/Expense, Net	$22.50K	$81.56K	$35.92K
YoY Change	-757.89%	127.08%
Pretax Income	-$12.75M	-$2.013M	-$3.918M
YoY Change	469.66%	-48.62%	-10.63%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$12.75M	-$2.013M	-$3.918M
YoY Change	469.66%	-48.62%	-10.63%
Net Earnings / Revenue		-26960.69%	-4552.91%
Basic Earnings Per Share		-$0.85	-$0.03
Diluted Earnings Per Share	-$4.92	-$0.85	-$33.56K
COMMON SHARES
Basic Shares Outstanding	2.569M shares	2.539M shares	116.7M shares
Diluted Shares Outstanding		2.356M shares	1.946M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.484M	$5.770M	$13.95M
YoY Change	-69.51%	-58.64%	-53.42%
Cash & Equivalents	$3.484M	$5.767M	$13.95M
Short-Term Investments
Other Short-Term Assets	$382.3K	$2.010M	$562.0K
YoY Change	-86.65%	257.68%	-4.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables		$35.10K
Total Short-Term Assets	$3.866M	$7.814M	$14.51M
YoY Change	-72.95%	-46.16%	-52.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.810K	$52.40K	$132.4K
YoY Change	-91.9%	-60.42%	-76.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.091M	$10.00K
YoY Change
Total Long-Term Assets	$1.101M	$85.34K	$527.8K
YoY Change	134.91%	-83.83%	-5.04%
TOTAL ASSETS
Total Short-Term Assets	$3.866M	$7.814M	$14.51M
Total Long-Term Assets	$1.101M	$85.34K	$527.8K
Total Assets	$4.966M	$7.899M	$15.04M
YoY Change	-66.35%	-47.48%	-51.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.245M	$810.0K	$871.1K
YoY Change	10.74%	-7.01%	-42.81%
Accrued Expenses	$240.5K	$45.28K	$202.0K
YoY Change	-70.41%	-77.58%	6.2%
Deferred Revenue
YoY Change
Short-Term Debt	$312.7K	$490.0K	$424.9K
YoY Change	16.84%	15.32%	-11.89%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.798M	$1.402M	$1.498M
YoY Change	12.65%	-6.4%	-31.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$204.6K
YoY Change	-100.0%	-100.0%	-41.41%
Total Long-Term Liabilities	$0.00		$204.6K
YoY Change	-100.0%		-41.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.798M	$1.402M	$1.498M
Total Long-Term Liabilities	$0.00		$204.6K
Total Liabilities	$1.798M	$1.402M	$1.703M
YoY Change	2.83%	-17.65%	-33.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$206.2M	-$193.5M	-$185.3M
YoY Change	11.13%	4.43%
Common Stock	$3.081K	$2.549K	$117.3K
YoY Change	52.15%	-97.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.168M	$6.497M	$13.34M
YoY Change
Total Liabilities & Shareholders Equity	$4.966M	$7.899M	$15.04M
YoY Change	-66.35%	-47.48%	-51.62%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$12.75M	-$2.013M	-$3.918M
YoY Change	469.66%	-48.62%	-10.63%
Depreciation, Depletion And Amortization	-$2.610K	$10.00K	$12.74K
YoY Change	-119.95%	-21.51%	32.16%
Cash From Operating Activities	-$1.101M	-$1.500M	-$3.776M
YoY Change	-54.75%	-60.27%	-27.11%
INVESTING ACTIVITIES
Capital Expenditures	$1.000M	$0.00	-$37.03K
YoY Change	28969.77%	-100.0%	53.52%
Acquisitions
YoY Change
Other Investing Activities	$3.720K	$60.00K	$0.00
YoY Change
Cash From Investing Activities	-$996.3K	$60.00K	-$37.03K
YoY Change	28861.63%	-262.03%	53.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-176.1K	730.0K	-103.5K
YoY Change	100.14%	-805.31%	-117.9%
NET CHANGE
Cash From Operating Activities	-1.101M	-1.500M	-3.776M
Cash From Investing Activities	-996.3K	60.00K	-37.03K
Cash From Financing Activities	-176.1K	730.0K	-103.5K
Net Change In Cash	-2.273M	-710.0K	-3.916M
YoY Change	-9.94%	-81.87%	-15.34%
FREE CASH FLOW
Cash From Operating Activities	-$1.101M	-$1.500M	-$3.776M
Capital Expenditures	$1.000M	$0.00	-$37.03K
Free Cash Flow	-$2.101M	-$1.500M	-$3.739M
YoY Change	-13.77%	-59.88%	-27.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001174940
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent		usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q3	OGEN	Stock Issued During Period Value Conversion Of Series B Preferred Stock To Common Stock StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock		usd
	OGEN	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets		usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
	OGEN	Conversion Of Stock Amount Converted ConversionOfStockAmountConverted		usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
	OGEN	Conversion Of Stock Amount Issued ConversionOfStockAmountIssued		usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent		usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent		usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-32188
	dei	Entity Registrant Name EntityRegistrantName	ORAGENICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-3410522
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4902 Eisenhower Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 125
	dei	Entity Address City Or Town EntityAddressCityOrTown	Tampa
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33634
	dei	City Area Code CityAreaCode	813
	dei	Local Phone Number LocalPhoneNumber	286-7900
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	OGEN
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2569385	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5766644	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11426785	usd
CY2023Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	35104	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2012344	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2844798	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	7814092	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	14271583	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52399	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	121062	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24337	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	347440	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	8600	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	17940	usd
CY2023Q3	us-gaap	Assets Assets	7899428	usd
CY2022Q4	us-gaap	Assets Assets	14758025	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	884350	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1124197	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	493420	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	267640	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24337	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	204447	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1402107	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1596284	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	152439	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	152439	usd
CY2023Q3	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2022Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	1592723	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1592723	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4166666	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4166666	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2569385	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2569385	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2024657	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2024657	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	2549	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2025	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	198372874	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	196977071	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-193470825	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185562517	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6497321	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13009302	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7899428	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14758025	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7466	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86047	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37653	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	131521	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	769350	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2777068	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4448623	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8660761	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1332562	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1215498	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3697609	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3592361	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2101912	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3992566	usd
	us-gaap	Operating Expenses OperatingExpenses	8146232	usd
	us-gaap	Operating Expenses OperatingExpenses	12253122	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2094446	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3906519	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8108579	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12121601	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	50613	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	41634	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	171768	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	68909	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	14170	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	5228	usd
	us-gaap	Interest Expense InterestExpense	18360	usd
	us-gaap	Interest Expense InterestExpense	9290	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	45118	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	46863	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11333	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	81561	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	36406	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	200271	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	70952	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2012885	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3870113	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7908308	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12050649	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2012885	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3870113	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7908308	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12050649	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.99
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.99
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.70
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.70
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.21
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2356065	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2356065	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1945747	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1945747	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2136340	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2136340	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1941858	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1941858	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13009302	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	79966	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2844837	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	10244431	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	63628	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3050586	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7257473	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	-1591	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	404516	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	849808	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2012885	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6497321	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	26486199	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	90247	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4590993	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	21985453	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	278988	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3589543	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	18674898	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	18674898	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	468545	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3870113	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	15273330	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	15273330	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7908308	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12050649	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27391	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	31594	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	22443	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	10964	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	546519	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	837780	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	35104	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-6987	usd
	OGEN	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-323103	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1443563	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1608905	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-9340	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-572396	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1490	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6188335	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12795647	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	63715	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	12000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	124081	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	63715	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-112081	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	385329	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	406921	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	849808	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	464479	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-406921	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5660141	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13314649	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11426785	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27265703	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5766644	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13951054	usd
	us-gaap	Interest Paid Net InterestPaidNet	3347	usd
	us-gaap	Interest Paid Net InterestPaidNet	9290	usd
	us-gaap	Notes Assumed1 NotesAssumed1	611109	usd
	us-gaap	Notes Assumed1 NotesAssumed1	528429	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	415169	usd
	OGEN	Conversion Of Stock Amount Converted ConversionOfStockAmountConverted	648821	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	400	usd
	OGEN	Conversion Of Stock Amount Issued ConversionOfStockAmountIssued	510	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7908308	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6188335	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-193470825	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zaRJjoy3jSj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zENiEUIODbBb">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal area of estimation reflected in the consolidated financial statements are estimates for research and development expenses and related prepaid and accrued expenses, which are based on the percentage of completion of the Company’s contracts with Contract Research Organizations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zTEOD4lmZjxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zOr6pGoPipbh">Reclassification</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_z8wOOH5MhNLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zzvvZsPORlQd">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes there is a minimal credit risk on cash and cash equivalents. Cash and cash equivalents could be adversely impacted, including the loss of uninsured deposits and other uninsured financial assets, if one or more of the financial institutions in which the Company holds its cash or cash equivalents fails or is subject to other adverse conditions in the financial or credit markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	OGEN	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	1468936	usd
CY2022Q4	OGEN	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	2471809	usd
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	535908	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	372989	usd
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	7500	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2012344	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2844798	usd
CY2023Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	808935	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	246690	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45276	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	812861	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	31101	usd
CY2023Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	30139	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	33545	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	884350	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1124197	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	493420	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	267640	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	493420	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	267640	usd
CY2022Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	reverse stock split of our common stock by a ratio of one for sixty
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	260995	shares
CY2023Q3	OGEN	Class Of Warrant Or Right Outstanding Exercisable ClassOfWarrantOrRightOutstandingExercisable	260995	shares
	OGEN	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodValue	1600	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	278988	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	278988	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	142003	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	369235	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	126896	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	404396	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	404396	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	0	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.040	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.430	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y5M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M19D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0624	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0578	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	14831	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9887	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	24718	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	381	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	24337	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	174442	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	114259	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1965	usd
	us-gaap	Lease Cost LeaseCost	174442	usd
	us-gaap	Lease Cost LeaseCost	116224	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	178339	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	117350	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-040060-index-headers.html	Edgar Link	pending
0001493152-23-040060-index.html	Edgar Link	pending
0001493152-23-040060.txt	Edgar Link	pending
0001493152-23-040060-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ogen-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
ogen-20230930_cal.xml	Edgar Link	unprocessable
ogen-20230930_def.xml	Edgar Link	unprocessable
ogen-20230930_lab.xml	Edgar Link	unprocessable
ogen-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OGEN
ORAGENICS INC Stock $ogen

2023 Q4 Form 10-Q Financial Statement

#000149315223040060 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGEN ORAGENICS INC Stock $ogen

2023 Q4 Form 10-Q Financial Statement

#000149315223040060 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGEN
ORAGENICS INC Stock $ogen